Enanta Pharmaceuticals (ENTA) Retained Earnings (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Retained Earnings of -$430.0 million for Q1 2026, down 3.14% on a QoQ basis from -$416.9 million in Q4 2025, and down 191845.54% year-over-year from N/an in Q1 2025.
Enanta Pharmaceuticals (ENTA) Retained Earnings (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' Retained Earnings history runs 15 years deep, the most recent figure standing at -$430.0 million for Q1 2026.
- Quarterly Retained Earnings fell 191845.54% year-over-year to -$430.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$430.0 million (down 191845.54% YoY) and the FY2025 annual result came in at -$339000.0, down 212.25% from the prior year.
- Retained Earnings was -$430.0 million for Q1 2026 at Enanta Pharmaceuticals, down from -$416.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at $302000.0 in Q3 2024 and bottomed at -$430.0 million in Q1 2026.
- A 5-year average of -$106.2 million and a median of -$3.0 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings jumped 125.72% — and 2025, when it plunged 1437372.41%.
- Enanta Pharmaceuticals' Retained Earnings stood at -$2.7 million in 2022, then sank by 8886.99% to -$240.4 million in 2023, then jumped by 99.99% to -$29000.0 in 2024, then plunged by 1437372.41% to -$416.9 million in 2025, then decreased by 3.14% to -$430.0 million in 2026.
- Business Quant data shows ENTA's Retained Earnings at -$430.0 million in Q1 2026, -$416.9 million in Q4 2025, and -$339000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Enanta Pharmaceuticals | 376.07 Mn | 212.29 Mn | - | -429.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -429.96 Mn |
| Dec 31, 2025 | -416.87 Mn |
| Sep 30, 2025 | -339,000.00 |
| Jun 30, 2025 | -402,000.00 |
| Mar 31, 2025 | -224,000.00 |
| Dec 31, 2024 | -29,000.00 |
| Sep 30, 2024 | 302,000.00 |
| Jun 30, 2024 | -653,000.00 |
| Mar 31, 2024 | -271.56 Mn |
| Dec 31, 2023 | -240.40 Mn |
| Sep 30, 2023 | -1.17 Mn |
| Jun 30, 2023 | -178.89 Mn |
| Mar 31, 2023 | -139.82 Mn |
| Dec 31, 2022 | -2.68 Mn |
| Sep 30, 2022 | -73.18 Mn |
| Jun 30, 2022 | -46.83 Mn |
| Mar 31, 2022 | -3.04 Mn |
| Dec 31, 2021 | -1.01 Mn |
| Sep 30, 2021 | 48.58 Mn |
| Jun 30, 2021 | -264,000.00 |